Group items tagged

"March 29, 2009 | Michael O'Riordan Orlando, FL - Reducing LDL cholesterol and high-sensitivity C-reactive protein (hs-CRP) in primary-prevention patients treated with rosuvastatin (Crestor, AstraZeneca) results in better event-free survival than when neither of these targets are achieved or when LDL cholesterol alone is reduced, a new analysis shows [1]. Presenting the results of the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study during an afternoon press conference at the American College of Cardiology 2009 Scientific Sessions, investigators say that initial interventions for low-risk primary-prevention patients remains lifestyle and dietary modifications, but for those choosing drug therapy, "reductions in both LDL cholesterol and hs-CRP are indicators of the success of treatment with statin therapy.""

"November 25, 2009 | Michael O'Riordan Orlando, FL - Treating healthy women with low LDL cholesterol but elevated high-sensitivity C-reactive protein (hsCRP) levels with rosuvastatin (Crestor, AstraZeneca) cuts their risk of cardiovascular events in half, according to a new analysis of Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). The reduction in risk is consistent with the reduction observed in the overall trial, and with the 42% benefit observed in men.

Miano L. [Mediterranean diet, micronutrients and prostate carcinoma: a rationale approach to primary prevention of prostate cancer] Arch Ital Urol Androl. 2003 Sep;75(3):166-78. Review. Italian. PMID: 14661397 [PubMed - indexed for MEDLINE]

Unusually prolonged vitamin D intoxication after discontinuation of vitamin D: possible role of primary hyperparathyroidism. Taskapan H, Vieth R, Oreopoulos DG. Int Urol Nephrol. 2008;40(3):801-5. Epub 2008 Jun 5. PMID: 18528779 DOI: 10.1007/s11255-008-9404-1

Primary vitamin D deficiency in adults.\nDrug Ther Bull. 2006 Apr;44(4):25-9. Review.\nPMID: 16617932 [PubMed - indexed for MEDLINE]

"Coconut oil is extracted from the kernel or meat of matured coconut harvested from the coconut palm (Cocos nucifera). Throughout the tropical world it has provided the primary source of fat in the diets of millions of people for generations. It has various applications in food, medicine, and industry. What makes coconut oil different from most other dietary oils is the basic building blocks or fatty acids making up the oil. Coconut oil is composed predominately of a special group of fat molecules known as medium chain fatty acids (MCFA). The majority of fats in the human diet are composed almost entirely of long chain fatty acids (LCFA). The primary difference between MCFA and LCFA is the size of the molecule, or more precisely, the length of the carbon chain that makes up the backbone of the fatty acid. MCFA have a chain length of 6 to 12 carbons. LCFA contain 14 or more carbon Historically, many populations within the tropics have used coconut medicinally as a treatment for a wide variety of ailments.[8] A study into the effects of a "diet rich in.." medium-chain fatty acids (such as in coconut oil and butter) concluded that "MCFAs in the form of MCTs significantly increased plasma triacylglycerol and LDL-cholesterol concentrations and the ratio of LDL to HDL cholesterol and thereby resulted in a less beneficial lipid profile overall."[9] Further, research done by nutritionist Mary Enig has found that non-hydrogenated coconut oil (i.e. extra-virgin) consumed in moderate amounts "is at worst neutral with respect to atherogenicity of fats and oils and, in fact, is likely to be a beneficial oil for prevention and treatment of some heart disease."[10] The lack of negative effects of a diet rich in coconut oil on cardiovascular health is born out in studies of Polynesian populations who consume as much as 65% of their calories in the form of coconut oil and yet, have almost no incidence of heart disease and normal blood lipid profiles.[11]

"18 645 patients with a total cholesterol of 6·5 mmol/L or greater were recruited from local physicians throughout Japan between 1996 and 1999. Patients were randomly assigned to receive either 1800 mg of EPA daily with statin (EPA group; n=9326) or statin only (controls; n=9319) with a 5-year follow-up. The primary endpoint was any major coronary event, including sudden cardiac death, fatal and non-fatal myocardial infarction, and other non-fatal events including unstable angina pectoris, angioplasty, stenting, or coronary artery bypass grafting. Analysis was by intention-to-treat. Findings At mean follow-up of 4·6 years, we detected the primary endpoint in 262 (2·8%) patients in the EPA group and 324 (3·5%) in controls-a 19% relative reduction in major coronary events (p=0·011). Post-treatment LDL cholesterol concentrations decreased 25%, from 4·7 mmol/L in both groups. Serum LDL cholesterol was not a significant factor in a reduction of risk for major coronary events. Unstable angina and non-fatal coronary events were also significantly reduced in the EPA group. Sudden cardiac death and coronary death did not differ between groups. In patients with a history of coronary artery disease who were given EPA treatment, major coronary events were reduced by 19% (secondary prevention subgroup: 158 [8·7%] in the EPA group vs 197 [10·7%] in the control group; p=0·048). In patients with no history of coronary artery disease, EPA treatment reduced major coronary events by 18%, but this finding was not significant (104 [1·4%] in the EPA group vs 127 [1·7%] in the control group; p=0·132)."

25-hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. Lou YR, Laaksi I, Syvälä H, Bläuer M, Tammela TL, Ylikomi T, Tuohimaa P. FASEB J. 2004 Feb;18(2):332-4. Epub 2003 Dec 4. PMID: 14657005

Macroscopical and histopathological changes in regressing primary and recurrent equine sarcoids during active specific bio-immunotherapy. Hallamaa RE, Saario E, Tallberg T. In Vivo. 2005 Jul-Aug;19(4):761-7. PMID: 15999546

Expanding the orbit of primary prevention--moving beyond JUPITER. Hlatky MA. N Engl J Med. 2008 Nov 20;359(21):2280-2. Epub 2008 Nov 9. PMID: 18997195

You ought to consume 3 primary meals daily, ie the morning meal, lunch and the evening meal

What causes coronary heart disease or coronary atherosclerotic plaque, this thing that we track with heart scans? Well, here are a few little-publicized facts about heart disease that you are unlikely to hear from your When's-the-next-stent? cardiologist or the What is there besides statins? primary care doctor. (Since everybody knows that smoking is a modifiable risk for heart disease that can be readily identified, let's focus on the blood tests that reveal heart disease causes.)

(NaturalNews) Zinc is an integral part of the male hormonal system, and a primary part of the semen. It plays a major role in the production of sperm. Studies also reveal that Zinc Deficiency may be a cause of Prostate Enlargement.\n\nAs men age into their 50s and older, there is a natural decline in zinc. A zinc deficiency can lead to prostate enlargement, as well as a number of other male problems including impotency. This is because the prostate tissues are highly dependent on zinc to maintain its health and integrity. Zinc increases sperm count and sperm motility. High zinc levels also mean lower levels of estrogen and prolactin thereby reducing the risk of prostate disease.

The Mediterranean Prescription: Meal Plans and Recipes to Help You Stay Slim and Healthy for the Rest of Your Life (Hardcover)\nby Laurie Anne Vandermolen (Collaborator), Angelo Acquista (Primary Contributor) \nHardcover: 320 pages\nPublisher: Ballantine Books (April 11, 2006)\nLanguage: English\nISBN-10: 0345479246\nISBN-13: 978-0345479242\n

Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J. \nn-3 Fatty acids from fish or fish-oil supplements, but not \nalpha-linolenic acid, benefit cardiovascular disease outcomes in \nprimary- and secondary-prevention studies: a systematic review. \nAm J Clin Nutr. 2006 Jul;84(1):5-17. Review. \nPMID: 16825676

Immune Protect with PARACTIN® contains a combination of patented ingredients that have been clinically shown to boost immune function, increasing the body's natural ability to combat challenges.* Immune Protect with PARACTIN® provides 100 milligrams of a proprietary, patented form of betaglucan that has been proven to activate the host immune system's primary defenders by activating complementary systems, enhancing macrophages and natural killer cell function.7-12* The immune cell-priming capabilities of this patented, highly purified yeast derivative exceed those of all other sources of immune supplements tested to date

Reports that vitamins C and E may blunt the positive effects of exercise are misleading, according to an antioxidant expert. German researchers have reported that antioxidant vitamins C and E may blunt the positive effects of exercise, with respect to insulin sensitivity. Findings were published in the Proceedings of the National Academy of Sciences. Reacting to the study , Alexander Schauss, PhD, from AIBMR Life Sciences, a nutraceutical products consultancy, told NutraIngredients.com that the title of the study (Antioxidants prevent health-promoting effects of physical exercise in humans) was misleading. "The primary objective of this study was to study the effect of a 4-week intensive 5-days a week exercise program on insulin sensitivity. Yet the title of the paper leads one to believe otherwise," he said. "This is a small gender-biased study of 40 male subjects, 25 to 35 years of age. When I read through the study for the first time I had to wonder how could the authors have come up with such a title for their paper?" he asked.

Benfotiamine (rINN, or S-benzoylthiamine O-monophoshate) is a synthetic S-acyl derivative of thiamine (vitamine B1). After absorption, benfotiamine can be dephosphorylated by cells bearing an ecto-alkaline phosphatase to the lipid-soluble S-benzoylthiamine. The primary use of this antioxidant is as an "anti-AGE" supplement.[3] In a trial, benfotiamine lowered AGE by 40%.[4] However, in Germany doctors have been known to combine benfotiamine with pyridoxine hydrochloride and use it to treat patients with nerve damage and nerve pain such as sciatica. At high doses, benfotiamine was shown to be effective for the treatment of diabetic retinopathy, neuropathy, and nephropathy. I

Vitamin D is safe when used in physiological doses (those used by Nature). Physiological doses are 3,000-5,000 IU/day, from all sources (sun, diet and supplements). Should hypercalcemia occur with such doses, it is due to vitamin D hypersensitivity syndrome, not vitamin D toxicity. Vitamin D hypersensitivity syndromes include conditions such as primary hyperparathyroidism, occult cancers (especially lymphoma) or granulomatous disease (especially sarcoidosis). In such cases, treatment of vitamin D deficiency should be done under the care of a knowledgeable physician. A serum 25(OH)D, serum 1,25(OH)D, PTH and SMA will lead the clinician in the right direction.